SG11201408011SA - Synthesis of antiviral compound - Google Patents
Synthesis of antiviral compoundInfo
- Publication number
- SG11201408011SA SG11201408011SA SG11201408011SA SG11201408011SA SG11201408011SA SG 11201408011S A SG11201408011S A SG 11201408011SA SG 11201408011S A SG11201408011S A SG 11201408011SA SG 11201408011S A SG11201408011S A SG 11201408011SA SG 11201408011S A SG11201408011S A SG 11201408011SA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- foster city
- gilead
- international
- lakeside drive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/184702 A1 (51) International Patent Classification: C07D 403/04 (2006.01) C07D 403/14 (2006.01) (21) International Application Number: (74) Agents: TANNER, Lorna, L. et al.; SHEPPARD MUL- LIN RICHTER & HAMPTON LLP, 379 Lytton Avenue, Palo Alto, CA 94301-1479 (US). (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/655,935 13/800,202 5 June 2012 (05.06.2012) 13 March 2013 (13.03.2013) (71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US). (72) Inventors: SCOTT, Robert, William; c/o Gilead Sci ences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). VITALE, Justin, Philip; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). MATTHEWS, Kenneth, Stanley; c/o Gilead Sci ences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). TERESK, Martin, Gerald; c/o Gilead Sci ences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). FORMELLA, Alexandra; c/o Gilead Sci ences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). EVANS, Jared, Wayne; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). PCT/US2013/044148 (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 4 June 2013 (04.06.2013) English English US US (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: SYNTHESIS OF ANTIVIRAL COMPOUND CJ o i> 00 T-H rn i-H (57) Abstract: The present disclosure provides processes for the preparation of compound a of formula I: (I), which is useful as an O antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I. N
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261655935P | 2012-06-05 | 2012-06-05 | |
US13/800,202 US9056860B2 (en) | 2012-06-05 | 2013-03-13 | Synthesis of antiviral compound |
PCT/US2013/044148 WO2013184702A1 (en) | 2012-06-05 | 2013-06-04 | Synthesis of antiviral compound |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408011SA true SG11201408011SA (en) | 2015-01-29 |
Family
ID=49671039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408011SA SG11201408011SA (en) | 2012-06-05 | 2013-06-04 | Synthesis of antiviral compound |
Country Status (17)
Country | Link |
---|---|
US (3) | US9056860B2 (en) |
EP (1) | EP2855454B1 (en) |
JP (3) | JP6181169B2 (en) |
KR (2) | KR102206434B1 (en) |
CN (2) | CN104520293B (en) |
AU (1) | AU2013271772B2 (en) |
BR (1) | BR112014030365A2 (en) |
CA (1) | CA2875508C (en) |
ES (1) | ES2587782T3 (en) |
HK (3) | HK1208670A1 (en) |
IL (2) | IL235941B (en) |
IN (1) | IN2014MN02496A (en) |
MX (1) | MX350892B (en) |
PT (1) | PT2855454T (en) |
RU (1) | RU2636943C2 (en) |
SG (1) | SG11201408011SA (en) |
WO (1) | WO2013184702A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1633766T (en) | 2003-05-30 | 2019-06-04 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
SI2709613T2 (en) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Methods for treating hcv |
US8969588B2 (en) | 2012-06-05 | 2015-03-03 | Gilead Pharmasset Llc | Solid forms of an antiviral compound |
US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
CN104211565A (en) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | Preparation method of anti-hepatitis c medicine intermediate |
MX2016002185A (en) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds. |
EP2883876A1 (en) * | 2013-12-16 | 2015-06-17 | Actelion Pharmaceuticals Ltd. | Stereoselective synthesis of substituted pyrrolidines |
TW202014413A (en) * | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | Processes for preparing antiviral compounds |
CN104513147B (en) * | 2014-11-20 | 2016-05-11 | 上海众强药业有限公司 | The preparation method of fluorenes ethanone derivatives |
CN104513223B (en) * | 2014-11-20 | 2017-07-14 | 上海众强药业有限公司 | The preparation method of fluorenes ethanone derivatives |
WO2016103232A1 (en) * | 2014-12-24 | 2016-06-30 | Granules India Limited | An improved process for the preparation of hcv inhibitor |
CN104530016A (en) * | 2014-12-25 | 2015-04-22 | 上海泓博智源医药技术有限公司 | Method for preparing Ledipasvir and intermediates of method for preparing Ledipasvir |
CN107427495A (en) | 2015-02-13 | 2017-12-01 | 桑多斯股份公司 | Include Lei Dipawei and Suo Feibuwei pharmaceutical composition |
WO2016145269A1 (en) | 2015-03-12 | 2016-09-15 | Teva Pharmaceuticals International Gmbh | Solid state forms ledipasvir and processes for preparation of ledipasvir |
CN104829599B (en) * | 2015-03-17 | 2017-06-09 | 上海众强药业有限公司 | The preparation method and the midbody compound for preparing Lei Dipawei of Lei Dipawei and its derivative |
CN104788361B (en) * | 2015-04-21 | 2017-06-30 | 杭州科巢生物科技有限公司 | The synthetic method of the formic acid derivates of 5 azaspiros [2.4] heptane 6 |
WO2016199049A1 (en) * | 2015-06-09 | 2016-12-15 | Hetero Research Foundation | Process for the preparation of ledipasvir |
CN104926796A (en) * | 2015-06-17 | 2015-09-23 | 南通常佑药业科技有限公司 | Preparation method for novel NS5A inhibitor medicine |
WO2016207915A1 (en) * | 2015-06-26 | 2016-12-29 | Mylan Laboratories Limited | Process for the preparation of ledipasvir |
CN105017228A (en) * | 2015-07-03 | 2015-11-04 | 上海众强药业有限公司 | Ledipasvir intermediate monosulfate, crystalline form thereof and preparation method therefor |
CN104961733B (en) | 2015-07-06 | 2019-04-09 | 上海众强药业有限公司 | Lei Dipawei crystal form and preparation method thereof |
KR101919194B1 (en) * | 2015-09-15 | 2018-11-15 | 주식회사 엘지화학 | Heterocyclic compound and organic light emitting device comprising the same |
CN105237516B (en) * | 2015-10-13 | 2018-01-02 | 厦门市蔚嘉化学科技有限公司 | A kind of Lei Dipawei preparation method |
CN105399657B (en) * | 2015-10-21 | 2017-10-10 | 海门慧聚药业有限公司 | Preparation of Ledipasvir key intermediate |
WO2017072596A1 (en) | 2015-10-26 | 2017-05-04 | Optimus Drugs (P) Ltd | An improved process for the preparation of ledipasvir |
CN105237384B (en) * | 2015-11-06 | 2017-06-30 | 上海万溯化学有限公司 | A kind of preparation method of polysubstituted fluorene derivative |
CN106892905A (en) * | 2015-12-17 | 2017-06-27 | 常州市勇毅生物药业有限公司 | A kind of preparation method of Lei Dipawei |
US20190062332A1 (en) * | 2016-02-01 | 2019-02-28 | Lupin Limited | Process for the preparation of ledipasvir and intermediates thereof |
WO2017145028A1 (en) * | 2016-02-26 | 2017-08-31 | Glenmark Pharmaceuticals Limited | Process for preparation of ledipasvir |
CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
CN109562107A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Heterocycle degron body for target protein degradation |
WO2017195147A1 (en) | 2016-05-12 | 2017-11-16 | Lupin Limited | Process for the preparation of ledipasvir and intermediates thereof |
CN106008316B (en) * | 2016-06-17 | 2018-04-27 | 成都百事兴科技实业有限公司 | A kind of method of synthesis Lei Dipawei chiral intermediates |
CN105968040B (en) * | 2016-06-29 | 2019-02-05 | 爱斯特(成都)生物制药股份有限公司 | A kind of preparation method of Lei Dipawei intermediate |
CN107641081A (en) * | 2016-07-22 | 2018-01-30 | 江苏威凯尔医药科技有限公司 | A kind of preparation method of pharmaceutical intermediate |
CN106349229B (en) * | 2016-08-25 | 2018-11-06 | 安徽华昌高科药业有限公司 | The preparation method and midbody compound of Lei Dipawei intermediates |
CN106632275B (en) * | 2016-12-20 | 2018-03-06 | 上海同昌生物医药科技有限公司 | The preparation method of Lei Dipawei a kind of and the intermediate for preparing Lei Dipawei |
US10392370B2 (en) | 2017-03-13 | 2019-08-27 | Optimus Drugs Pvt Ltd | Process for the preparation of Daclatasvir dihydrochloride and its intermediates |
CN107488685A (en) * | 2017-06-13 | 2017-12-19 | 南京方生和医药科技有限公司 | (S) the enzymology preparation method of the carboxylic acid of 5 azaspiros [2.4] heptane 6 and its derivative |
CN107879908A (en) * | 2017-11-14 | 2018-04-06 | 安徽诺全药业有限公司 | A kind of Lei Dipawei key intermediates and preparation method thereof |
CN107954990A (en) * | 2017-11-14 | 2018-04-24 | 安徽诺全药业有限公司 | A kind of preparation method of Lei Dipawei |
CN108753863A (en) * | 2018-06-14 | 2018-11-06 | 慎终(上海)生物科技有限公司 | The synthesis technology of Lei Dipawei intermediates |
WO2020077071A1 (en) * | 2018-10-10 | 2020-04-16 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (fasn) |
TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
EP3885339A1 (en) * | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof |
CN112851545B (en) * | 2020-07-08 | 2022-09-20 | 日照巴洛特药业有限公司 | Synthetic process of Ledipasvir intermediate |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003519698A (en) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | High-throughput formation, identification and analysis of various solid forms |
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
TWI410422B (en) * | 2007-01-15 | 2013-10-01 | Mitsubishi Tanabe Pharma Corp | Condensed tetrahydroquinoline derivative and its medical use |
EP2242752B1 (en) * | 2008-02-13 | 2012-08-08 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
US8232409B2 (en) * | 2008-10-15 | 2012-07-31 | Janssen Pharmaceutica N.V. | Heterocyclic benzimidazoles as TRPM8 modulators |
DK2430014T3 (en) | 2009-05-13 | 2015-11-30 | Gilead Pharmasset Llc | Anti-viral compounds |
EP2475256A4 (en) * | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
EP2504315A1 (en) * | 2009-11-23 | 2012-10-03 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
TW201211047A (en) | 2010-06-10 | 2012-03-16 | Gilead Sciences Inc | Methods for treating HCV |
US8969588B2 (en) | 2012-06-05 | 2015-03-03 | Gilead Pharmasset Llc | Solid forms of an antiviral compound |
US9056860B2 (en) * | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
-
2013
- 2013-03-13 US US13/800,202 patent/US9056860B2/en active Active
- 2013-06-04 WO PCT/US2013/044148 patent/WO2013184702A1/en active Application Filing
- 2013-06-04 EP EP13729208.2A patent/EP2855454B1/en active Active
- 2013-06-04 CN CN201380029806.7A patent/CN104520293B/en active Active
- 2013-06-04 KR KR1020147036884A patent/KR102206434B1/en active IP Right Grant
- 2013-06-04 BR BR112014030365A patent/BR112014030365A2/en active Search and Examination
- 2013-06-04 AU AU2013271772A patent/AU2013271772B2/en active Active
- 2013-06-04 IN IN2496MUN2014 patent/IN2014MN02496A/en unknown
- 2013-06-04 SG SG11201408011SA patent/SG11201408011SA/en unknown
- 2013-06-04 JP JP2015516145A patent/JP6181169B2/en active Active
- 2013-06-04 MX MX2014014569A patent/MX350892B/en active IP Right Grant
- 2013-06-04 ES ES13729208.2T patent/ES2587782T3/en active Active
- 2013-06-04 RU RU2014150435A patent/RU2636943C2/en not_active IP Right Cessation
- 2013-06-04 CN CN201710524415.2A patent/CN107266428A/en active Pending
- 2013-06-04 PT PT137292082T patent/PT2855454T/en unknown
- 2013-06-04 KR KR1020207015492A patent/KR20200066376A/en not_active Application Discontinuation
- 2013-06-04 CA CA2875508A patent/CA2875508C/en active Active
-
2014
- 2014-11-27 IL IL235941A patent/IL235941B/en not_active IP Right Cessation
-
2015
- 2015-05-05 US US14/704,627 patent/US20150232453A1/en not_active Abandoned
- 2015-09-22 HK HK15109284.9A patent/HK1208670A1/en unknown
- 2015-10-12 HK HK15109928.1A patent/HK1209124A1/en unknown
- 2015-10-12 HK HK18104959.1A patent/HK1245273A1/en unknown
-
2016
- 2016-08-04 US US15/228,825 patent/US9718807B2/en active Active
-
2017
- 2017-06-14 JP JP2017116558A patent/JP6356876B2/en active Active
-
2018
- 2018-03-25 IL IL258327A patent/IL258327A/en unknown
- 2018-06-14 JP JP2018113637A patent/JP6594487B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408011SA (en) | Synthesis of antiviral compound | |
SG11201407533SA (en) | Antiviral compounds | |
SG11201408013WA (en) | Solid forms of an antiviral compound | |
SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
SG11201407596TA (en) | Conjugation reagents | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
SG11201408047XA (en) | Macrocyclic inhibitors of flaviviridae viruses | |
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201408064PA (en) | Macrocyclic inhibitors of flaviviridae viruses | |
SG11201408261UA (en) | Syringe | |
SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
SG11201407774XA (en) | Conversion of biomass | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201407115XA (en) | Carboxylic acid compounds | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201408045UA (en) | MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES | |
SG11201407189XA (en) | C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity | |
SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
SG11201810479WA (en) | Precision applicator |